These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
211 related articles for article (PubMed ID: 28332991)
1. Accelerated Total Lymphoid Irradiation-containing Salvage Regimen for Patients With Refractory and Relapsed Hodgkin Lymphoma: 20 Years of Experience. Rimner A; Lovie S; Hsu M; Chelius M; Zhang Z; Chau K; Moskowitz AJ; Matasar M; Moskowitz CH; Yahalom J Int J Radiat Oncol Biol Phys; 2017 Apr; 97(5):1066-1076. PubMed ID: 28332991 [TBL] [Abstract][Full Text] [Related]
2. Patterns of Failure and Survival Outcomes after Total Lymphoid Irradiation and High-Dose Chemotherapy with Autologous Stem Cell Transplantation for Relapsed or Refractory Classical Hodgkin Lymphoma. Paudel N; Schulze D; Gentzler RD; Evens AM; Helenowski I; Dillehay G; Frankfurt O; Mehta J; Donnelly ED; Gordon LI; Winter JN; Mittal BB Int J Radiat Oncol Biol Phys; 2019 Jun; 104(2):436-446. PubMed ID: 30763660 [TBL] [Abstract][Full Text] [Related]
3. A 2-step comprehensive high-dose chemoradiotherapy second-line program for relapsed and refractory Hodgkin disease: analysis by intent to treat and development of a prognostic model. Moskowitz CH; Nimer SD; Zelenetz AD; Trippett T; Hedrick EE; Filippa DA; Louie D; Gonzales M; Walits J; Coady-Lyons N; Qin J; Frank R; Bertino JR; Goy A; Noy A; O'Brien JP; Straus D; Portlock CS; Yahalom J Blood; 2001 Feb; 97(3):616-23. PubMed ID: 11157476 [TBL] [Abstract][Full Text] [Related]
4. Outcome analysis of high-dose chemotherapy and autologous stem cell transplantation in adolescent and young adults with relapsed or refractory Hodgkin lymphoma. Akhtar S; Rauf SM; Elhassan TA; Maghfoor I Ann Hematol; 2016 Sep; 95(9):1521-35. PubMed ID: 27376363 [TBL] [Abstract][Full Text] [Related]
5. Ifosfamide, idarubicin, and etoposide in relapsed/refractory Hodgkin disease or non-Hodgkin lymphoma: a salvage regimen with high response rates before autologous stem cell transplantation. Oyan B; Koc Y; Ozdemir E; Kars A; Turker A; Tekuzman G; Kansu E Biol Blood Marrow Transplant; 2005 Sep; 11(9):688-97. PubMed ID: 16125639 [TBL] [Abstract][Full Text] [Related]
6. High-dose chemotherapy with or without total body irradiation followed by autologous bone marrow and/or peripheral blood stem cell transplantation for patients with relapsed and refractory Hodgkin's disease: results in 85 patients with analysis of prognostic factors. Nademanee A; O'Donnell MR; Snyder DS; Schmidt GM; Parker PM; Stein AS; Smith EP; Molina A; Stepan DE; Somlo G Blood; 1995 Mar; 85(5):1381-90. PubMed ID: 7858268 [TBL] [Abstract][Full Text] [Related]
7. Accelerated hyperfractionated total-lymphoid irradiation, high-dose chemotherapy, and autologous bone marrow transplantation for refractory and relapsing patients with Hodgkin's disease. Yahalom J; Gulati SC; Toia M; Maslak P; McCarron EG; O'Brien JP; Portlock CS; Straus DJ; Phillips J; Fuks Z J Clin Oncol; 1993 Jun; 11(6):1062-70. PubMed ID: 8501492 [TBL] [Abstract][Full Text] [Related]
8. Phase I/II trial of total lymphoid irradiation and high-dose chemotherapy with autologous stem-cell transplantation for relapsed and refractory Hodgkin's lymphoma. Evens AM; Altman JK; Mittal BB; Hou N; Rademaker A; Patton D; Kaminer L; Williams S; Duffey S; Variakojis D; Singhal S; Tallman MS; Mehta J; Winter JN; Gordon LI Ann Oncol; 2007 Apr; 18(4):679-88. PubMed ID: 17307757 [TBL] [Abstract][Full Text] [Related]
9. Prognostic factors and long-term outcome of autologous haematopoietic stem cell transplantation following a uniform-modified BEAM-conditioning regimen for patients with refractory or relapsed Hodgkin lymphoma: a single-center experience. Czyz A; Lojko-Dankowska A; Dytfeld D; Nowicki A; Gil L; Matuszak M; Kozlowska-Skrzypczak M; Kazmierczak M; Bembnista E; Komarnicki M Med Oncol; 2013; 30(3):611. PubMed ID: 23702734 [TBL] [Abstract][Full Text] [Related]
10. Peritransplant Radiation Therapy in Patients With Refractory or Relapsed Hodgkin Lymphoma Undergoing Autologous Stem Cell Transplant: Long-Term Results of a Retrospective Study of the Fondazione Italiana Linfomi. Levis M; Campbell BA; Matrone F; Grapulin L; Di Russo A; Buglione M; Iamundo De Cumis I; Simontacchi G; Ciammella P; Magli A; Pascale G; Meregalli S; MacManus M; Fanetti G; De Felice F; Furfaro G; Ciccone G; Ricardi U Int J Radiat Oncol Biol Phys; 2023 Aug; 116(5):1008-1018. PubMed ID: 36822373 [TBL] [Abstract][Full Text] [Related]
11. Does the addition of involved field radiotherapy to high-dose chemotherapy and stem cell transplantation improve outcomes for patients with relapsed/refractory Hodgkin lymphoma? Kahn S; Flowers C; Xu Z; Esiashvili N Int J Radiat Oncol Biol Phys; 2011 Sep; 81(1):175-80. PubMed ID: 20732769 [TBL] [Abstract][Full Text] [Related]
12. Involved field radiation therapy following high dose chemotherapy and autologous stem cell transplant benefits local control and survival in refractory or recurrent Hodgkin lymphoma. Biswas T; Culakova E; Friedberg JW; Kelly JL; Dhakal S; Liesveld J; Phillips GL; Constine LS Radiother Oncol; 2012 Jun; 103(3):367-72. PubMed ID: 22398312 [TBL] [Abstract][Full Text] [Related]
13. F-18 FDG-PET predicts outcomes for patients receiving total lymphoid irradiation and autologous blood stem-cell transplantation for relapsed and refractory Hodgkin lymphoma. Gentzler RD; Evens AM; Rademaker AW; Weitner BB; Mittal BB; Dillehay GL; Petrich AM; Altman JK; Frankfurt O; Variakojis D; Singhal S; Mehta J; Williams S; Kaminer L; Gordon LI; Winter JN Br J Haematol; 2014 Jun; 165(6):793-800. PubMed ID: 24628515 [TBL] [Abstract][Full Text] [Related]
15. Impact of Risk Factors and Long Term Survival Analysis of Patients With Primary Refractory Hodgkin Lymphoma Who Underwent High Dose Chemotherapy and Autologous Stem Cell Transplant. Akhtar S; Rauf MS; Elhassan TAM; Khan ZA; Elshenawy MA; Maghfoor I Transplant Cell Ther; 2023 Jul; 29(7):451.e1-451.e12. PubMed ID: 37031748 [TBL] [Abstract][Full Text] [Related]
16. Long-term results of high-dose chemotherapy with autologous bone marrow or peripheral stem cell transplant as first salvage treatment for relapsed or refractory Hodgkin lymphoma: a single institution experience. Viviani S; Di Nicola M; Bonfante V; Di Stasi A; Carlo-Stella C; Matteucci P; Magni M; Devizzi L; Valagussa P; Gianni AM Leuk Lymphoma; 2010 Jul; 51(7):1251-9. PubMed ID: 20528244 [TBL] [Abstract][Full Text] [Related]
17. Phase I study of involved-field radiotherapy preceding autologous stem cell transplantation for patients with high-risk lymphoma or Hodgkin's disease. Dawson LA; Saito NG; Ratanatharathorn V; Uberti JP; Adams PT; Ayash LJ; Reynolds CM; Silver SM; Schipper MJ; Lichter AS; Eisbruch A Int J Radiat Oncol Biol Phys; 2004 May; 59(1):208-18. PubMed ID: 15093918 [TBL] [Abstract][Full Text] [Related]
18. Role of salvage radiation therapy for patients with relapsed or refractory hodgkin lymphoma who failed autologous stem cell transplant. Goda JS; Massey C; Kuruvilla J; Gospodarowicz MK; Wells W; Hodgson DC; Sun A; Keating A; Crump M; Tsang RW Int J Radiat Oncol Biol Phys; 2012 Nov; 84(3):e329-35. PubMed ID: 22672755 [TBL] [Abstract][Full Text] [Related]
19. High-dose chemotherapy in relapsed or refractory Hodgkin lymphoma patients: a reappraisal of prognostic factors. Cocorocchio E; Peccatori F; Vanazzi A; Piperno G; Calabrese L; Botteri E; Travaini L; Preda L; Martinelli G Hematol Oncol; 2013 Mar; 31(1):34-40. PubMed ID: 22473680 [TBL] [Abstract][Full Text] [Related]
20. Lomustine, cytarabine, cyclophosphamide, etoposide - An effective conditioning regimen in autologous hematopoietic stem cell transplant for primary refractory or relapsed lymphoma: Analysis of toxicity, long-term outcome, and prognostic factors. Gupta A; Gokarn A; Rajamanickam D; Punatar S; Thippeswamy R; Mathew L; Bagal B; Kannan S; Khattry N J Cancer Res Ther; 2018; 14(5):926-933. PubMed ID: 30197327 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]